• Agios licensed cevidoplenib, a next-generation SYK inhibitor, expanding into immune thrombocytopenia, an estimated $3 billion-plus global market by 2030.
• Deal terms include a USD 25 million upfront payment, up to USD 140 million in development and regulatory milestones, tiered royalties from high single digits to mid-teens.
• Management pegged the U.S. commercial opportunity at up to USD 1 billion in peak annual sales, targeting about 24,000 refractory patients.
• Phase 2 met a key durability endpoint: 50% achieved at least two consecutive platelet counts ≥30,000/µL vs 8.3% on placebo (p=0.015).
• Phase 3 is planned for the first half of 2028, with FY 2026 OpEx expected to be roughly flat vs FY 2025 excluding the upfront payment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.